Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CD20/anti-CD3 bispecific IgM antibody IGM2323

An engineered immunoglobulin M (IgM) bispecific antibody, with potential antineoplastic activity. Anti-CD20/CD3 bispecific IgM antibody IGM2323 contains ten high affinity binding domains for the tumor-associated antigen (TAA) CD20, and one binding domain for CD3, a T-cell surface antigen. Upon administration, IGM2323 binds to both T cells and CD20-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD20-expressing tumor B cells. Additionally, IGM-2323 induces complement-dependent cytotoxicity (CDC) to a greater extent than anti-CD20/anti-CD3 IgG bispecific antibodies, thereby further enhancing the killing CD20-expressing tumor cells. The extra binding units of IGM-2323 may bind cancer cells that express relatively low amounts of CD20. Also, compared to IgG format bispecific T-cell engaging antibodies, IGM2323 appears to induce less cytokine release, which may reduce the risk of cytokine release syndrome (CRS). CD20 is exclusively expressed on B-cells during most stages of B cell development and is often overexpressed in B-cell malignancies.
Synonym:bispecific CD20xCD3 IgM antibody IGM2323
bispecific IgM antibody IGM2323
IgM pentamer IGM2323
Code name:IGM 2323
IGM-2323
IGM2323
Search NCI's Drug Dictionary